Want to see MEDS full AI Analyst Report?
MEDS Stock Chart & Stats
$0.14
--
Market closed
$0.14
--
Day’s Range― - ―
52-Week Range$1.26 - $97.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.82M
Market Cap
$4.21M
Enterprise Value$38.16M
Total Cash (Recent Filing)$51.73K
Total Debt (Recent Filing)$28.91M
Price to Earnings (P/E)―
Beta0.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,847,198
10 Day Avg. Volume1,367,507
30 Day Avg. Volume28,820,997
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap9.07
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit-3.93
Enterprise Value/Ebitda-0.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Rebrand & Vertical IntegrationThe company renamed operating subsidiaries and organized a pharmacy-focused division to enable vertical integration of healthcare delivery. Structurally, this realignment can strengthen control over margins, enable cross-selling across care and distribution, and create clearer operating units for strategic partnerships or divestitures.
Improving Free Cash Flow TrendAlthough FCF remains negative, the 16.5% improvement versus the prior annual period signals a nascent trend toward lower cash burn. Sustained improvement in FCF over quarters would reduce reliance on external financing and indicate operational adjustments beginning to take hold, a durable benefit if maintained.
Tangible Asset BaseA tangible asset base of roughly $30.1M provides a balance-sheet cushion to support operations, restructuring, or collateral for financing. For a distressed operator, meaningful assets improve restructuring optionality and lender confidence versus a purely intangible footprint, a structural advantage in recovery scenarios.
Bears Say
Sharp Revenue DeclineA nearly 40% TTM revenue drop indicates lost customer demand or market share and undermines scale economics. Persistent top-line erosion makes fixed-cost absorption harder, weakens negotiating leverage with suppliers, and lengthens the timeline to restore profitability absent a clear, sustainable revenue turnaround.
Deeply Negative MarginsExtremely negative gross and net margins reflect structural problems in pricing, cost of goods sold, or business mix. Such losses destroy equity, complicate reinvestment, and mean the company must materially alter operations or pricing to ever reach sustainable profitability; this is a persistent strategic weakness.
Stressed Capital Structure & Cash BurnNegative equity combined with sizable debt and continued negative operating cash flow creates refinancing and solvency risk. This capital structure limits flexibility for investments or M&A, raises cost of capital, and makes the company dependent on external financing until operations generate sustained positive cash flow.
DataMeds AI News
MEDS FAQ
What was DataMeds AI’s price range in the past 12 months?
DataMeds AI lowest stock price was $1.25 and its highest was $97.50 in the past 12 months.
What is DataMeds AI’s market cap?
DataMeds AI’s market cap is $4.21M.
When is DataMeds AI’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were DataMeds AI’s earnings last quarter?
Currently, no data Available
Is DataMeds AI overvalued?
According to Wall Street analysts DataMeds AI’s price is currently Overvalued.
Does DataMeds AI pay dividends?
DataMeds AI does not currently pay dividends.
What is DataMeds AI’s EPS estimate?
DataMeds AI’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DataMeds AI have?
DataMeds AI has 2,847,198 shares outstanding.
What happened to DataMeds AI’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DataMeds AI?
Currently, no hedge funds are holding shares in MEDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DataMeds AI
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
Technical Analysis
―
Prestige Consumer Healthcare
―
―
Synergy CHC
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
18.97% Insiders
15.89% Mutual Funds
― Other Institutional Investors
64.75% Public Companies and
Individual Investors